Cargando…

Role of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy

INTRODUCTION: Accumulating evidence now indicates that insulin-like growth factors (IGF) and their regulatory proteins are growth promoters for arterial cells and mediators of cardiovascular diseases. AIM: We hypothetised that IGF-1 levels could play a role in the development of stent thrombosis (ST...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yalcin, Ahmet Arif, Topuz, Mustafa, Biyik, Ismail, Akturk, Ibrahim Faruk, Celik, Omer, Isıksacan, Nilgun, Yalcın, Burce, Birant, Ali, Uzun, Fatih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252321/ https://www.ncbi.nlm.nih.gov/pubmed/25489317 http://dx.doi.org/10.5114/pwki.2014.46765

Ejemplares similares

The role of insulin-like growth factor-1 in development of coronary no-reflow and severity of coronary artery disease in patients with acute myocardial infarction
por: Akturk, Ibrahim Faruk, et al.
Publicado: (2014)

Antiplatelet resistance and the role of associated variables in stable patients treated with stenting
por: Uzun, Fatih, et al.
Publicado: (2015)

Left ventricular steal syndrome caused by multiple plexiform coronary artery fistulae: case report, literature review and treatment
por: Biyik, İsmail, et al.
Publicado: (2016)

Immunosuppressive therapy induced coronary vasospasm and acute myocardial infarction in a patient undergoing new renal transplantation
por: Biyik, Ismail, et al.
Publicado: (2015)

Can thrombectomy and catheters used increase angiographically visible distal embolization in ST elevation myocardial infarction?
por: Sarikamis, Cetin, et al.
Publicado: (2016)

The Predictors of Asymptomatic Cerebral Embolism After Carotid Artery Stenting
por: Güner, Ahmet, et al.
Publicado: (2022)

Presepsin (sCD14-ST): could it be a novel marker for the diagnosis of ST elevation myocardial infarction?
por: Caglar, Fatma Nihan Turhan, et al.
Publicado: (2017)

Does contrast media volume affect long-term survival in patients with chronic kidney disease?
por: Biyik, Ismail, et al.
Publicado: (2017)

Serum Presepsin Levels Are Not Elevated in Patients with Controlled Hypertension
por: Biyik, Ismail, et al.
Publicado: (2018)

Usefulness of the platelet-to-lymphocyte ratio in predicting long-term cardiovascular mortality in patients with peripheral arterial occlusive disease
por: Uzun, Fatih, et al.
Publicado: (2017)

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
por: Cho, Min Soo, et al.
Publicado: (2017)

Simultaneous Thrombosis of Two Drug-Eluting Stents After Discontinuation of Dual Antiplatelet Therapy for a Day
por: Chen, Hung Yi
Publicado: (2012)

Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy
por: Sudhir, Krishnankutty, et al.
Publicado: (2013)

In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report
por: Nagrani, Tarun, et al.
Publicado: (2010)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Subacute Stent Thrombosis in a Patient With COVID-19 Despite Adherence to Antiplatelets
por: Elkholy, Karim O, et al.
Publicado: (2021)

The correlation between plasma human neutrophil peptide 1-3 levels and severity of coronary artery disease
por: Ungan, Ismail, et al.
Publicado: (2016)

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
por: Benezet-Mazuecos, Juan, et al.
Publicado: (2007)

Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
por: Jhang, Kai-Ming, et al.
Publicado: (2015)

Very Late Stent Thrombosis 42 Months after Implantation of Sirolimus-Eluting Stent and Discontinuation of Antiplatelet Therapy
por: Sibbing, Dirk, et al.
Publicado: (2009)

Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation
por: Poorhosseini, Hamid Reza, et al.
Publicado: (2012)

Very Late Thrombosis of a Drug-Eluting Stent After Discontinuation of Dual Antiplatelet Therapy in a Patient Treated With Both Drug-Eluting and Bare-Metal Stents
por: Kim, Sung Soo, et al.
Publicado: (2009)

Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio in Missed Abortion
por: Biyik, Ismail, et al.
Publicado: (2020)

Is there any association between vitamin D levels and isolated coronary artery ectasia?
por: Ciftci, Serkan, et al.
Publicado: (2016)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

Clinical Presentations, Antiplatelet Strategies and Prognosis of Patients with Stent Thrombosis: An Observational Study of 140 Patients
por: Han, Ya-Ling, et al.
Publicado: (2012)

Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials
por: Lin, Bei-you, et al.
Publicado: (2019)

Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
por: Hobson, Alex R, et al.
Publicado: (2008)

Impact of early (3 months) dual antiplatelet treatment interruption prior to renal transplantation in patients with second-generation DES on perioperative stent thrombosis and MACEs
por: Doğan, Ali, et al.
Publicado: (2017)

Emerging trends of online assessment systems in the emergency remote teaching period
por: Topuz, Arif Cem, et al.
Publicado: (2022)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries
por: Kronlage, Mariya, et al.
Publicado: (2017)

Is the Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents the Longer the Better?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
por: Kao, Chih-Chin, et al.
Publicado: (2021)

Protease‐activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model
por: Berry, Jess, et al.
Publicado: (2022)

The Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus
por: Sahingoz Erdal, Gulcin, et al.
Publicado: (2021)

Association between soluble lectin-like oxidized low-density lipoprotein receptor 1 levels and coronary slow flow phenomenon
por: Caglar, Ilker Murat, et al.
Publicado: (2016)

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021)

Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone
por: Uzun, Rusen, et al.
Publicado: (2016)

Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials
por: Huang, Feng
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_djsv5s610d2imc9rc25t1oakl9